All Industries

PathAI Expands Portfolio of AI-Powered Products, Announcing PathExplore™ IOP and IHC Explore™ Ahead of ASCO 2024

PathAI

PathAI, a global leader in AI-powered pathology, unveiled two novel AI products, PathExplore™ Immuno-Oncology Profiling (IOP) and IHC Explore 1 ™ to empower cancer drug developers and clinical researchers with AI-powered insights. The product pairing provides unprecedented single-cell and spatial resolution of the tumor microenvironment from routine pathology samples to facilitate biomarker discovery and deeper understanding of treatment response for the next generation of cancer therapeutics. The expansion of the Explore™ portfolio comes at a time when AI-pathology is experiencing accelerated large-scale adoption across the diagnostic and biopharma industries. “As cancer rates continue to rise, the demand for advanced precision medicine tools that provide accurate biological insights has never been greater. Our mission to make a difference in patient lives is unwavering, and these new products showcase our commitment to providing researchers with the tools they need to make meaningful advancements in cancer research, treatment and care,” said Andy Beck, PathAI CEO. “We're thrilled to introduce these two groundbreaking products ahead of the American Society of Clinical Oncology annual meeting.” PathExplore IOP: H&E-Based Immune Phenotyping The composition of the tumor immune microenvironment plays a crucial role in characterizing tumors likely to respond to immunotherapy. PathExplore IOP expedites characterization of immune phenotypes by quantifying tumor infiltrating lymphocytes (TILs) and their spatial distribution using routine hematoxylin and eosin (H&E) samples. With this new product, researchers have the ability to quantify TIL spatial arrangements within tumor core and periphery, and gain insights around the sample’s immune inflamed, desert, or excluded characteristics. PathExplore IOP was designed specifically to quantify patterns of immune infiltration characteristic of a strong immune response, and ultimately improved patient survival. Immune infiltration has been previously shown to be prognostic of positive outcomes, however; standardized and scalable approaches for investigating these phenotypes remained elusive. “PathExplore IOP illustrates the power of AI by visually interrogating the dynamics between cancer cells and immune cells with unparalleled resolution for highly accurate and efficient immune phenotype classification,” said Benjamin Glass, VP of Product & Translational Research. “Researchers can now access insights at scale to better inform biomarker strategies for patient stratification and mechanisms of response and resistance.” PathExplore IOP will be featured in a poster presentation at the upcoming ASCO 2024 meeting, demonstrating the product’s application for stratification of patient response to checkpoint inhibitors in non-small cell lung cancer. IHC Explore™: AI-Powered Biomarker Quantification Immunohistochemistry (IHC) is a widely utilized approach for identifying biomarkers unique to certain cancers, informing treatment strategies, measuring prognosis, and patient classification for clinical trials. IHC scoring in the early clinical settings can be time-consuming, subjective, and low-resolution. Especially in early stage biomarker development, defining an optimal scoring system for a novel IHC assay can be complex. IHC Explore™ fills a need for spatial quantification of IHC biomarkers in single-cell resolution with broad target compatibility. IHC Explore provides a panel of standardized and structured features that quantify IHC stain abundance within and around cells of the tumor microenvironment, enabling drug developers to build biomarker scoring strategies from scratch for most IHC stains – and to precisely find those patients most responsive to treatment. PathAI’s partnership with Roche streamlines the translation of these AI insights and scoring strategies into companion diagnostic development. “Drawing on our advanced computational pathology expertise, we're extending the impact of our Explore product suite, which enables us to seamlessly support AI-powered assay development,” said Hisani Madison, VP of Precision Medicine and Medical Device Development. “This advancement is poised to revolutionize biomarker-based drug development for new immunotherapies, antibody drug conjugates, and paving the way for the analysis of the next generation of targeted cancer therapies.” Accepted Abstracts at ASCO 2024 PathAI will be attending and presenting abstracts at the upcoming ASCO event in Chicago, IL. Visit PathAI’s booth in the Innovation Hub (IH18) May 31- June 4, 2024 to meet our team, learn more about AI-powered pathology, and engage with our scientists and collaborators at their respective posters. Footnotes 1 PathExplore™ IOP and IHC Explore™ are for research use only. Not for use in diagnostic procedures. About PathAI PathAI is the leading precision pathology company providing software and AI-enabled solutions to all pathologist stakeholders including laboratories, research institutions, and the biopharma industry. Developed with the input of hundreds of pathologists, PathAI’s digital pathology Image Management System, AISight, is the solution of choice for laboratories transitioning to digital workflows. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

May 29, 2024 10:00 AM Eastern Daylight Time

Quadrise Signs Commercial Framework Agreement with Moroccan client for MSAR Supply

Quadrise PLC

Quadrise CEO Jason Miles joined Steve Darling from Proactive to announce the signing of a significant Commercial Framework Agreement with OCP S.A., an international manufacturing and mining group based in Morocco. This agreement marks a major milestone for Quadrise as it opens new commercial avenues for the supply of their proprietary MSAR® fuel technology to OCP. Miles detailed that the agreement initiates commercial discussions with third parties to secure MSAR® supply to OCP. Concurrently, Quadrise and OCP have agreed to collaborate on a paid-for commercial trial at OCP's Jorf Lasfar site. This trial is a crucial step in demonstrating the feasibility and benefits of using MSAR® fuel in OCP’s operations. To meet OCP's demand, Quadrise will engage with potential suppliers, including refineries, terminal operators, and traders, who have the capacity to produce MSAR®. Facilitating these discussions, OCP has signed a Letter of Intent, indicating their commitment to entering into a Commercial Supply Agreement with a supplier that will provide MSAR® under a license from Quadrise. Additionally, Quadrise will update the technical, economic, and feasibility study that was previously issued in June 2022. This update will focus on converting the Jorf Lasfar site for the consumption of MSAR®. Quadrise will also supply and install the necessary equipment to emulsify locally available heavy fuel oil using MSAR® technology. Following this setup, a 30-day MSAR® combustion trial will be conducted on a kiln at the site. The execution of the Commercial Supply Agreement will be contingent upon the successful results of this trial. Miles emphasized that this agreement with OCP not only validates the potential of MSAR® technology but also represents a significant step forward in Quadrise’s strategic growth plan. The collaboration with OCP, one of the world's leading fertilizer producers, underscores the increasing recognition and adoption of MSAR® as a cleaner and more efficient alternative to traditional heavy fuel oil. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 29, 2024 09:04 AM Eastern Daylight Time

Video

OneMeta's AI Transforms Global Communication With Cutting-Edge Translation And Transcription

Benzinga

By Meg Flippin, Benzinga Though it has its downsides, in the right hands, Artificial intelligence (AI) can help overcome communication barriers, enhance human interactions and automate complex business processes. Thanks to AI and machine learning, computers and digital devices can recognize, understand and produce text and speech. ChatGPT, the popular AI chatbot developed by OpenAI and Microsoft Corp. (NASDAQ: MSFT), is an example of the power of NLP – but it's not the only one. Translate And Transcribe In Seconds OneMeta Inc. (OTC: ONEI), the AI-powered translation and transcription services company headquartered in Bountiful, Utah, is making a name for itself thanks to its advanced technology that translates and transcribes spoken and written words in seconds across multiple languages. Its technology can be used in various settings and across industries, including education, finance, healthcare and legal. Whether attending a live event, participating in an online meeting or talking on the phone, OneMeta's technology offers real-time speech translation and transcription with live captions. Its VerbumCall product enables real-time translation over the phone in more than 150 languages. Meanwhile, VerbumOnSite enables attendees at live events to scan a QR code to access real-time captions in over 150 languages directly on their phones. Microsoft Likes It Then there’s Verbum for Microsoft Teams, which allows multilingual groups to come together in meetings. Each attendee chooses the language they are speaking in and the language they want to see captions and chat in. As each person speaks in their preferred language from a list of 95+ languages, it is translated in near real-time for the rest of the group. In April, OneMeta’s Verbum for Microsoft Teams received Microsoft Co-Sell Ready Status which means its product was added to Microsoft’s Teams store, AppSource Marketplace and the Azure Marketplace. That will likely boost the product’s recognition and drive sales. "Since OnceMeta just achieved Microsoft Co-Sell Ready Status we are seeing significant interest from potential customers who want to apply the Verbum software to their usage of Microsoft Teams in the 140+ languages we offer,” said OneMeta CEO Saul Leal. “We can bring our AI for translation and transcription to all enterprises without compromising privacy, compliance and data security," Alessandro Balzarelli, director at Microsoft Industry Solutions Engineering, concurred, saying the software giant expects to see Verbum’s adoption and growth by enterprises that need multi-language translation and transcription pick up. “Verbum empowers Microsoft Teams users to be more efficient and more inclusive within their own organizations and with their own customers," he said. After researching various niche industries where AI technologies would have a disruptive impact, OneMeta selected NLP technology to pursue because it believes it will have the most measurable impact and economic traction in the months to come. It's also a big business. In 2023, the global natural language processing market was valued at $24.10 billion. By 2032, it is expected to reach $158.04 billion, growing at a CAGR of 23.2% during the forecast period. Breaking Barriers, Landing New Customers OneMeta is also constantly enhancing its technology to be even faster and more seamless. That drive was on display recently when the company announced it reduced the translation and transcription speed of over 150 languages and dialects to less than 200 milliseconds. OneMeta said the breakthrough allows for the near-instantaneous interpretation of spoken content into multiple languages simultaneously, all on the same audio channel. The process is so swift it is virtually unnoticeable to both listeners and readers, surpassing the speed and accuracy of human interpreters and any existing competitive technologies, OneMeta reports. “Unlike traditional human interpreters who need to hear a full sentence before beginning translation, our technology operates on simultaneous near-real-time interpretation. This means audiences can follow conversations in real-time without the delays typically required for translation,” said Leal. “As a result, meetings can proceed at their scheduled pace, potentially reducing the time spent in meetings by up to 70%. This efficiency not only streamlines communication but also represents significant cost savings for our clients in their interpretation and translation budgets." The benefits were enough for OneMeta to land the Archdiocese of Oklahoma City as a new customer. The Archdiocese is using Verbum translation and transcription services to communicate with its multicultural parishioners. OneMeta expects more Archdioceses in many countries to adopt its technology. AI is here to stay, and while there are reasons to be concerned, with the right companies this technology can disrupt and transform industries, break down communication barriers and connect the world wherever people are. OneMeta recognizes the power of AI and has created a stack of AI-driven products that remove the language barriers that keep people apart. With demand for NLP growing, the OneMeta story is one to watch. Featured photo by Markus Spiske on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 29, 2024 08:45 AM Eastern Daylight Time

Image

PipFarm Enters Trader Evaluation And Funding Niche With Experience-Focused Program

Benzinga

By Gerelyn Terzo, Benzinga A recently launched funded trader firm named PipFarm, led by seasoned industry executive James Glyde, has been garnering some attention since it launched in March. As the former chief commercial officer of cTrader, Glyde launched PipFarm with cTrader as a solution to recent trading platform disruptions that have left online traders scrambling. Existing prop trading firm players experienced operational disruptions recently amid restrictions involving access to MetaQuotes platforms. They struggled to recover from the situation, due to no backup or continuity plan. Traders have essentially been left out in the cold, with many feeling like there are no suitable alternative platforms to use. Due to the latest industry disruptions, many traders and even prop firm founders are led to believe the current prop-trading model is unsustainable, blaming the business model itself. In reality, the failure can largely be traced back to the leadership level. The industry’s knee-jerk response to market disruptions has been the introduction of new evaluation models, including the implementation of 2% daily profit caps. The caps are meant to prevent gambler-like activity. But they’ve backfired among traders who are missing out on opportunities, especially during strong market movements in which traders typically thrive. Instead of fostering traders’ ambitions, many firms started punishing traders with the gambler stigma and gaslighting. But if many prop firms are honest, they’d admit that if they didn’t have enough money to pay out traders after a period of downtime, it means they did not have enough liquidity to begin with. Take prop trading giant True Forex Funds, which sadly was forced to shutter its operations permanently after facing a worst-case scenario in which it went bankrupt. Thousands of traders were left with more questions than answers around whether or not they’d get their money back. True Forex Funds CEO Richard Nagy blamed the MetaQuotes fiasco, which set off a chain of events including the depletion of savings that resulted in the firm’s insolvency. Fortunately, traders have another alternative: PipFarm. The platform seeks to usher in the next generation of forex traders with its battle-tested cTrader platform, known for its stability and user friendliness for traders at all levels. Volatile financial markets have taken a toll on prop trading. For instance, U.S.-based The Funded Trader was forced to pause operations due to customer payout issues. Other firms that were also shut down include Skilled Funded Traders and My Forex Funds. This response left traders with fewer choices for funding opportunities, causing them to wonder if their best days were behind them. The truth is the next chapter of online trading has only just begun, for the right players. In this environment, online traders need to be more selective about their trading partners more than ever. So, what inspired PipFarm’s founder to launch amid such a volatile landscape? PipFarm’s secret weapon is Glyde’s vast experience in the fintech and online trading worlds. Glyde spent over a decade as a fintech executive, so he understands the risk management paradigm. cTrader integration also highlights the company’s commitment to stability, especially in light of the fact that MetaQuotes recently terminated support for multiple brokers, pushing them to integrate alternative platforms like cTrader. “Unlike most of our competitors, we built our own dashboard and risk management system, giving us unlimited flexibility to innovate our product,” said Glyde. Glyde’s unique perspective is needed in the industry now more than ever considering recent market developments that have left many prop trading firms with a regulatory target on their backs. Instead of sitting on the sidelines and watching as the industry caves to changing rules, he decided to do something about it with the creation of a new firm and funding program. Funded Trader Platform Mechanics As a funded-traded platform, PipFarm allows remote forex traders to trade with the firm’s capital and share in the profits. Upon passing a trading evaluation, you can qualify for up to $200,000 in funding. The more successful you are, the more funding will be extended to you to continue upward on your growth path. When traders uncover successful trading strategies, the firm is also able to harness those ideas for its own activities. PipFarm won’t dictate your trading strategy, whether it’s automatic or manual. Glyde is interested in empowering users and helping them to grow while offering support along the journey. Some of the key features of PipFarm’s first-generation cTrader platform include: Payouts: Earn payments for the pips generated in your account. Keep up to 90% of the pips you earn. Your profit share is commensurate with your trading performance. Leverage: PipFarm offers 1:30 maximum leverage by product. Scaling: Meet targets and get rewarded with additional funding rounds. With access to lower commissions, higher leverage and anytime payouts, PipFarm’s model is transparent. Their main priority is to set forex traders up for success. Traders looking to make their next move may benefit from PipFarm’s cTrader capabilities, branding and features. Those who do so will be able to say they were a part of the original PipFarm funded trader platform that delivers lifetime perks to the forex community. Get started with your funded trading journey with PipFarm by clicking here! Featured photo by sergeitokmakov on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 29, 2024 08:35 AM Eastern Daylight Time

Image

City-Owned Utility Selects Siyata Mobile’s (NASDAQ: SYTA) Budget-Friendly Mission-Critical PTT Handset To Connect Its Workers And Keep Utilities Running Smoothly

Siyata Mobile Inc.

By Faith Ashmore, Benzinga When we think of extreme careers, we may not automatically think of utility work, but we should. Utility fieldwork is one of the most demanding jobs, and it can involve working in extreme conditions or following disasters. When anything goes wrong and utilities – like natural gas, water, sewage or refuse collection – go offline, the public needs utilities on as soon as possible. This is where effective communication is essential for field crews to stay in constant communication and respond to situations with ease. Land Mobile Radios (LMR) have been the traditional communication solution used by field workers for many decades. However, these handheld radios were big, bulky and costly to carry around, making them cumbersome for everyday use. Push To Talk (PTT) radio coverage provided by LMR technology was also often limited to a short distance, usually covering one city or one county, and was prone to no coverage zones, where communication was unreliable. The limitations of LMR technology have been a source of frustration for field workers, dispatchers and their command staff. A few years ago, some industries switched to smartphones to ensure constant communication, but even that has not panned out as expected. Smartphones have apps and capabilities that are not needed and can be a distraction for many workers, and many smartphones are less weather-resistant than other communication devices that are designed to endure extreme conditions. The Public Utilities department from Lancaster, Ohio, recently selected Siyata Mobile Inc. (NASDAQ: SYTA) (“Siyata”), a global developer and vendor of mission-critical Push To Talk (PTT) over Cellular handsets and accessories, as a communications solution. Utility workers there support the city’s natural gas, water, wastewater treatment, stormwater drainage and refuse collection. They will now be using Siyata’s SD7 mission-critical PTT handsets, which will replace previously used two-way radios that operated on their own radio network. This department decided to switch to Siyata's handsets due to the cost savings and operational benefits they offer. Previously, the Public Utilities department would purchase two-way radios for approximately $2000 per unit. After conducting a Total Cost of Ownership analysis, the city concluded that moving to Push-to-Talk over Cellular (PoC) using FirstNet Extended Primary PoC service would be more cost-effective. FirstNet is the perfect network to support communications needs when critical infrastructure needs to be fixed or installed. The Siyata SD7 Handset was deemed the ideal device choice for the city's Public Utilities staff. It is affordable through FirstNet since its price and the PTT service were spread over 24 months, and it is rugged and simple to use – similar to two-way radios – making it a good fit for staff who were already accustomed to using radios. Also, the SD7 handsets work seamlessly with Siyata’s VK7 Vehicle Kits used in their trucks. Charlie Mullett, Traffic Control Supervisor from Lancaster’s Department of Transportation, commented, “We chose the Siyata SD7 unit along with the VK7 Vehicle Kit because we like the versatility of having the high performance PTT Communication as a mobile rugged handheld or as a docked unit in our transportation vehicles. We also chose them because of the FirstNet ready capability. They have worked well for our needs and we have received great customer service and support from the FirstNet Solutions Team.” The SD7 handsets and VK7 Vehicle Kits have already been integrated into the crew's day-to-day operations. With a track record as a pioneer in the industry and with solutions catering to various uses in a wide variety of industries, Siyata has earned its reputation for reliability and versatility. Featured photo courtesy of Knelson20 on Shutterstock. Siyata Mobile Inc. is a B2B global vendor of next-generation Push-To-Talk over Cellular devices, cellular booster systems, and video monitoring solutions. Its portfolio of in-vehicle and rugged devices enables first responders and enterprise workers to instantly communicate, over a nationwide cellular network of choice, to increase situational awareness and save lives.Its portfolio of enterprise-grade and consumer cellular booster systems enables first responders and enterprise workers to amplify cellular signals in remote areas, inside structural buildings where signals are weak, and within vehicles for the maximum cellular signal strength possible.For its video monitoring system, Siyata integrates software that we license with off-the-shelf hardware providing our customers with an integrated advanced camera system for management and visual monitoring of their fleet vehicles. This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on Siyata's current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of Siyata could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Siyata's filings with the Securities and Exchange Commission ("SEC") and in subsequent filings with the SEC. Except as otherwise required by law, Siyata undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites and social media have been provided as a convenience, and the information contained on such websites or social media is not incorporated by reference into this press release. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Brett Maas SYTA@haydenir.com

May 29, 2024 08:30 AM Eastern Daylight Time

Image

Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets

Benzinga

By Faith Ashmore, Benzinga The global retinoblastoma treatment market size was estimated to be $2.62 billion in 2023 and is expected to reach $4.20 billion by 2034 with a CAGR of 4.38% over 2024-2034. Rising incidence of retinoblastoma, early diagnosis and treatment, increasing healthcare expenditure, growing awareness of retinoblastoma treatment options, development of new treatments and government initiatives will drive the market’s growth. Recently, the FDA granted accelerated approval to Iovance Biotherapeutics’ (NASDAQ: IOVA) lifileucel (Amtagvi) to treat inoperable or metastatic melanoma, making it the first and only one-time tumor-infiltrating lymphocyte (TIL) therapy to be greenlighted for solid tumors. Lifileucel is manufactured by collecting and expanding a patient’s unique T cells from part of their tumor and then infusing them into that patient to fight the cancer. Oncotelic Therapeutics (OTCQB: OTLC) is looking to develop similar treatment therapies for ocular cancers, including retinoblastoma and uveal melanoma. The technology is named necroptosis therapies. Oncotelic and Mosaic ImmunoEngineering, Inc. (OTC: CPMV) are developers of necroptosis therapies. The recent approval of TIL cell therapy demonstrates how to manipulate patient immunity against cancer for a lasting cure. However, TIL cell therapy is costly, time-consuming and technologically challenging. Instead of driving TIL cells externally, Necroptosis Cancer Therapies drive innate TILs to the tumor. The key step is the induction of necrotic cell death and activation of death genes, exposing tumor-reactive antigens to initiate an immune response, activating antigen-presenting cells to achieve large-scale antigen presentation, activating T-cells, inducing strong and sustained cytotoxic T lymphocyte responses, and ultimately triggering a TIL antitumor immune effect. Necroptosis Cancer Therapies can use vascular disrupting agents (“VDA”), in combination with CheckPoint Inhibitors and other IO agents to drive TIL cells to the tumor. Oncotelic Therapeutics recently announced a binding term-sheet agreement with Mosaic ImmunoEngineering. Under this arrangement, Mosaic will acquire the rights to Oncotelic's clinical-stage necroptosis cancer therapies. These innovative therapeutics disrupt tumor blood flow, leading to immunogenic tumor cell death through the activation of "death receptors" – ultimately triggering a potent anti-cancer immune response. As part of the deal, Mosaic will also gain access to Oncotelic's AI technologies for identifying immunotherapy combinations. "We are very pleased to have this opportunity to bring these clinical stage assets that have promise for the treatment of multiple types of cancer into Mosaic. We anticipate that the initial application of the technology will be in areas with high unmet medical need such as uveal melanoma and retinoblastoma. We look forward to working with the Oncotelic team to advance the program," said Steven King, President and CEO of Mosaic. As outlined in the binding term sheet, Mosaic will issue $15 million in CPMV shares to Oncotelic upon the execution of the definitive purchase agreement. Additional milestones will enable Oncotelic to earn up to an extra $15 million in CPMV shares. The experienced Mosaic team, with a collective background encompassing more than 30 FDA and worldwide product approvals, will spearhead the advancement of these technologies. Both companies will collaborate closely to ensure the smooth transfer of technologies from Oncotelic to Mosaic, with Oncotelic providing short-term financial support for the program while working together toward achieving short-term and long-term financing goals. "This will be the second transaction for capitalizing on our assets and building shareholder value. The first being the successful transition of OT-101 to our joint venture (“JV”) with Dragon Capital Overseas, Limited. The JV is expected to list for an IPO and has been expanding its R&D including the completion of its research and manufacturing facility headquartered in San Diego, California." shared Dr. Vuong Trieu, CEO of Oncotelic. Pipeline – What More To Expect From Oncotelic Oncotelic has multiple drugs in its pipeline, such as ArtiVeda/ArtiShield, a COVID drug that aims to inhibit the spread of the virus; OT-101 for the treatment of solid tumors with a focus on brain cancer in adults and diffuse intrinsic pontine glioma in children; CA4P, which is intended to be used with Ipilimumab for the treatment of solid tumors with focus on melanoma; Oxi4503 for the treatment of liquid tumors with focus on childhood leukemia; and AL-101, an intranasal drug for the treatment of Parkinson Disease that also targets Erectile Dysfunction and Female Sexual Dysfunction. Oncotelic is looking to develop these drugs using a similar JV structure, which should enhance shareholder values. With an encouraging recent announcement and an extensive pipeline, Oncotelic may be a company to watch as it continues its endeavors to provide patients with more efficient treatments – with fewer side effects. Featured photo by Olga Kononenko on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 29, 2024 08:30 AM Eastern Daylight Time

Image

AI UNLEASHED: EXPLORING THE POSSIBILITIES

Benzinga

Benzinga is excited to announce its upcoming webinar, "AI UNLEASHED: EXPLORING THE POSSIBILITIES," scheduled for Thursday, May 30th, at 11 AM EST. This engaging virtual event will dive into the power of artificial intelligence and its potential to revolutionize industries. Participants will explore everything from machine learning algorithms to AI-driven products and services, and learn how companies are leveraging AI to reshape the business landscape. Details: Title: AI UNLEASHED: EXPLORING THE POSSIBILITIES Date: Thursday, May 30, 2024 Time: 11:00 AM EST Description: Artificial intelligence is transforming industries at an unprecedented pace. This webinar will explore the latest developments in AI, discussing machine learning algorithms, AI-driven products and services, and how companies are integrating AI to innovate and stay competitive. Gain insights from industry experts on the future of AI and its impact on various sectors. Speakers: Jeff Ransdell, Fuel Venture Capital Justis Mendez, OneSixOne Ventures Akash Palkhiwala, Qualcomm Kedar Kondap, Qualcomm Luke Lloyd, Luke Lloyd Michael Lee, Michael Lee Strategy Stephanie Link, Hightower Advisors Paul Chang, Brand Engagement Network Peter M. Carlson, Spectral MD This is a free virtual event. Don't miss this opportunity to gain valuable insights into the future of AI. Register Here! For further details and registration, please visit the event registration page. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. Contact Details Benzinga +1 877-440-9464 drew@benzinga.com Company Website http://www.benzinga.com

May 29, 2024 08:25 AM Eastern Daylight Time

Classiq collaborates with Hewlett Packard Enterprise on Hybrid Quantum Simulation

Classiq Technologies

Classiq, a leading quantum software company, announced it has developed a rapid method for solving large-scale combinatorial optimization problems in collaboration with Hewlett Packard Labs, the central research community of Hewlett Packard Enterprise (HPE), the result of joint research on the integration of high performance computing (HPC) and quantum computing. The rising level of maturity on the diverse approaches to quantum computation is now raising questions about how to productively integrate leading edge quantum and classical HPC approaches to solve important problems to the top of the research agenda. As the demand for sophisticated computational solutions increases, the integration between HPC and quantum computing is becoming crucial. From scheduling and orchestration to hybrid computation, these two approaches are converging, creating opportunities for innovative solutions to complex problems. This collaboration between Classiq and Hewlett Packard Labs exemplifies the potential of combining state-of-the-art classical and quantum algorithms to achieve superior results The hybrid approach uses the HPE Cray Supercomputing EX system and the massive parallel execution efficiency of HPE Cray Programming Environment for high performance computing along with the Classiq synthesis engine's ability to synthesize Quantum Approximate Optimization Algorithm (QAOA) circuits to achieve noteworthy results. This solution encapsulates smaller problems to formulate an optimal approach for large-scale challenges. By merging classical and quantum algorithms, this method demonstrates a significant improvement in solving real-world problems efficiently and how to make the potential advantages of quantum acceleration readily available in the HPC data center. The work will be showcased in the paper titled “Hybrid Classical-Quantum Simulation of MaxCut using QAOA-in-QAOA,” to be presented on the 31st May at the Q-Casa workshop at the IEEE IPDPS Conference in San Francisco. “This collaboration is a testament to the power of combining cutting-edge quantum and classical computing technologies. We are incredibly proud of the work we have done together, which not only showcases the potential of hybrid computation but also demonstrates tangible efficiency improvements,” said Nir Minerbi, CEO of Classiq. “The findings in this paper are a significant step forward in accelerating the integration of quantum computing into mainstream applications.” Integration of the Classiq engine as backend to Hewlett Packard Labs quantum programming environment will enable abstract, optimized and scalable quantum/HPC software development. By continuing to innovate and develop new solutions, both companies aim to drive the accelerated integration of these key computational technologies, paving the way for future advancements in various industries. HPE’s venture capital program, Hewlett Packard Pathfinder, made a 2022 investment in Classiq. About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing platform (IDE, compiler and OS) with a single point of entry into quantum computing, taking you from algorithm design to execution. The high-level descriptive quantum software development environment, tailored to all levels of developer proficiency, automates quantum programming. This ensures that a broad range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of quantum physics. Classiq democratizes access to quantum computing and equips its users to take full advantage of the quantum computing revolution, including access to a broad range of quantum hardware. Classiq’s core technology, algorithmic quantum circuit compilation, is engineered to power the quantum ecosystem of today and the future. Classiq works closely with quantum cloud providers and advanced computation hardware developers providing software for use with quantum computers, HPC and quantum simulators. Backed by investors such as Hewlett Packard Enterprise’s Hewlett Packard Pathfinder venture capital program, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking quantum engine. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, visit the Slack community, GitHub repository and website, www.classiq.io to learn more. Contact Details Rainier Communications Jenna Beaucage +1 508-340-6851 jbeaucage@rainierco.com Company Website http://www.classiq.io/

May 29, 2024 08:05 AM Eastern Daylight Time

Tractor Supply Presents on SHARE Series

SHARE Series

Contact Details SHARE Series Dan Aldridge +1 404-740-0638 dan@shareconferenceseries.com Company Website https://share-series.open-exchange.net

May 29, 2024 08:00 AM Eastern Daylight Time

Video

1 ... 167 168 169 170 171 ... 3753

Back